UNSPSC 51430000: Antihypertensive drugs

This classification denotes drugs used in the treatment of acute or chronic vascular hypertension - or persistently high systemic arterial blood pressure - regardless of pharmacological mechanism. among the antihypertensive agents are diuretics; (especially diuretics, thiazide); adrenergic beta-antagonists; adrenergic alpha-antagonists; angiotensin-converting enzyme inhibitors; calcium channel blockers; ganglionic blockers; and vasodilator agents.

UNSPSC 51430000 Antihypertensive drugs is a Family code that covers acute-care medications used in emergency medical services and institutional pharmacy settings. State and local governments procure these drugs primarily for fire rescue departments, hospital systems, and multistate pharmacy benefit programs serving public employees and beneficiaries. The Tampa Fire Rescue solicitation illustrates the core work: sealed-bid procurement of specific drug formulations (labetalol, epinephrine, adenosine, diltiazem) in measured quantities with firm pricing, nine-month minimum expiration dates, rapid delivery windows, and one-year initial contract terms with renewal options. The Minnesota cooperative purchasing initiative demonstrates a broader institutional model, where multistate alliances aggregate demand across participating jurisdictions and require manufacturers to supply through authorized wholesalers with NDC-specific product data, cGMP and DSCSA compliance certification, and flexible net-pricing structures. Issuing bodies include city purchasing departments, state health agencies, and multistate cooperative purchasing organizations; Tampa's SLBE sheltered-market designation with a 5 percent bid discount illustrates local set-aside practice in this space.

Recent activity spans Florida, Texas, and Minnesota with broader multistate participation through cooperative purchasing vehicles. The City of Tampa's Advanced Life Support Medications IFB (due April 8, 2026, estimated value $40,000) and the Minnesota Multistate Cooperative Purchasing Alliance's Generic Multi Source Pharmaceuticals RFP (due March 26, 2026) represent the two dominant procurement models—direct municipal supply and aggregated multistate contracting. The Texas Health and Human Services Commission's Request for Information on Direct-to-Manufacturer Prescriptions (April 3, 2026) signals emerging state-level interest in manufacturer direct-contracting models to bypass traditional pharmacy benefit manager intermediaries, though no formal procurement timeline or budget was specified in that exploratory phase.